| RF |
Report |
NII (Q2 2026) |
IN-LINE |
pred ~$1,278M vs. cons $1,275M |
MEDIUM |
| RF |
Report |
NIM FTE (Q2 2026) |
IN-LINE |
pred ~3.68% vs. cons 3.66% |
MEDIUM |
| RF |
Report |
Adj. Fee Income (Q2 2026) |
IN-LINE |
pred ~$650M vs. cons $646M |
MEDIUM |
| RF |
Guide |
FY 2026 NII (FY 2026) |
UNCHANGED |
guide '2.5-4% growth' reiterated vs. cons $5,149M |
HIGH |
| RF |
Guide |
FY 2026 Adj. Fee Income (FY 2026) |
UNCHANGED |
guide '3-5% growth' reiterated vs. cons $2,644M |
HIGH |
| RF |
Guide |
FY 2026 NCOs (FY 2026) |
UNCHANGED |
guide '40-50 bps' reiterated; tone toward lower end vs. cons 0.47% |
MEDIUM |
| RF |
Guide |
Q3 2026 NII direction (Q3 2026) |
UNCHANGED |
continued expansion guided vs. implied ~$1,295M |
MEDIUM |
| RF |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
MEDIUM |
| RF |
Return |
5-day cumulative residual |
-0.5% (STABILIZE) |
STABILIZE — initial sell-off on beat + reiterate into elevated stock; partial recovery as H2 NII math is digested and no negative surprises emerge |
MEDIUM |